Zobrazeno 1 - 10
of 505
pro vyhledávání: '"Bomalaski, J"'
Autor:
Abou-Alfa, G.K. *, Qin, S., Ryoo, B.-Y., Lu, S.-N., Yen, C.-J., Feng, Y.-H., Lim, H.Y., Izzo, F., Colombo, M., Sarker, D., Bolondi, L., Vaccaro, G., Harris, W.P., Chen, Z., Hubner, R.A., Meyer, T., Sun, W., Harding, J.J., Hollywood, E.M., Ma, J., Wan, P.J., Ly, M., Bomalaski, J., Johnston, A., Lin, C.-C., Chao, Y., Chen, L.-T.
Publikováno v:
In Annals of Oncology June 2018 29(6):1402-1408
Autor:
Szlosarek PW; Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.; The Mid and South Essex University Hospitals Group, Chelmsford, United Kingdom.; Barts Cancer Centre, St Bartholomew's Hospital, London, United Kingdom., Creelan BC; H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida., Sarkodie T; The Mid and South Essex University Hospitals Group, Chelmsford, United Kingdom., Nolan L; Southampton University Hospital NHS Foundation Trust, Southampton, United Kingdom., Taylor P; Manchester University NHS Foundation Trust, Wythenshawe Hospital, Manchester, United Kingdom., Olevsky O; David Geffen School of Medicine at UCLA, Los Angeles, California., Grosso F; Mesothelioma Unit, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy., Cortinovis D; Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy., Chitnis M; Oxford Cancer and Haematology Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom., Roy A; University Hospitals Plymouth NHS Trust, Plymouth, United Kingdom., Gilligan D; Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge, United Kingdom., Kindler H; University of Chicago Medicine, Chicago, Illinois., Papadatos-Pastos D; University College London Hospitals, London, United Kingdom., Ceresoli GL; Cliniche Humanitas Gavazzeni, Bergamo, Italy., Mansfield AS; Mayo Clinic, Rochester, Minnesota., Tsao A; The University of Texas MD Anderson Cancer Center, Houston., O'Byrne KJ; Princess Alexandra Hospital and Queensland University of Technology, Brisbane, Australia., Nowak AK; Medical School, The University of Western Australia and Sir Charles Gairdner Hospital, Perth, Western Australia., Steele J; Barts Cancer Centre, St Bartholomew's Hospital, London, United Kingdom., Sheaff M; Barts Cancer Centre, St Bartholomew's Hospital, London, United Kingdom., Shiu CF; Polaris Pharmaceuticals, Inc, San Diego, California., Kuo CL; Polaris Pharmaceuticals, Inc, San Diego, California., Johnston A; Polaris Pharmaceuticals, Inc, San Diego, California., Bomalaski J; Polaris Pharmaceuticals, Inc, San Diego, California., Zauderer MG; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York., Fennell DA; University of Leicester & University Hospitals of Leicester NHS, United Kingdom.
Publikováno v:
JAMA oncology [JAMA Oncol] 2024 Apr 01; Vol. 10 (4), pp. 475-483.
Autor:
Phillips MM; Center for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute (BCI)-a Cancer Research UK Center of Excellence, Queen Mary University of London, John Vane Science Center, London, EC1M 6BQ, UK.; Department of Medical Oncology, Barts Health NHS Trust, St Bartholomew's Hospital, West Smithfield, London, EC1A 7BE, UK., Pavlyk I; Center for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute (BCI)-a Cancer Research UK Center of Excellence, Queen Mary University of London, John Vane Science Center, London, EC1M 6BQ, UK., Allen M; Center for Tumor Microenvironment, Barts Cancer Institute (BCI)-a Cancer Research UK Center of Excellence, Queen Mary University of London, John Vane Science Center, London, EC1M 6BQ, UK., Ghazaly E; Centre for Haemato-Oncology, Barts Cancer Institute (BCI)-a Cancer Research UK Center of Excellence, Queen Mary University of London, John Vane Science Center, London, EC1M 6BQ, UK.; Medicines and Healthcare Products Regulatory Agency (MHRA), London, UK., Cutts R; Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK., Carpentier J; Center for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute (BCI)-a Cancer Research UK Center of Excellence, Queen Mary University of London, John Vane Science Center, London, EC1M 6BQ, UK., Berry JS; Center for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute (BCI)-a Cancer Research UK Center of Excellence, Queen Mary University of London, John Vane Science Center, London, EC1M 6BQ, UK., Nattress C; Center for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute (BCI)-a Cancer Research UK Center of Excellence, Queen Mary University of London, John Vane Science Center, London, EC1M 6BQ, UK., Feng S; Center for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute (BCI)-a Cancer Research UK Center of Excellence, Queen Mary University of London, John Vane Science Center, London, EC1M 6BQ, UK., Hallden G; Center for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute (BCI)-a Cancer Research UK Center of Excellence, Queen Mary University of London, John Vane Science Center, London, EC1M 6BQ, UK., Chelala C; Center for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute (BCI)-a Cancer Research UK Center of Excellence, Queen Mary University of London, John Vane Science Center, London, EC1M 6BQ, UK., Bomalaski J; Polaris Pharmaceuticals, Inc., San Diego, CA, 92121, USA., Steele J; Department of Medical Oncology, Barts Health NHS Trust, St Bartholomew's Hospital, West Smithfield, London, EC1A 7BE, UK., Sheaff M; Department of Histopathology, Barts Health NHS Trust, Royal London Hospital, London, E1 1BB, UK., Balkwill F; Center for Tumor Microenvironment, Barts Cancer Institute (BCI)-a Cancer Research UK Center of Excellence, Queen Mary University of London, John Vane Science Center, London, EC1M 6BQ, UK., Szlosarek PW; Center for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute (BCI)-a Cancer Research UK Center of Excellence, Queen Mary University of London, John Vane Science Center, London, EC1M 6BQ, UK. p.w.szlosarek@qmul.ac.uk.; Department of Medical Oncology, Barts Health NHS Trust, St Bartholomew's Hospital, West Smithfield, London, EC1A 7BE, UK. p.w.szlosarek@qmul.ac.uk.
Publikováno v:
Pharmacological reports : PR [Pharmacol Rep] 2023 Jun; Vol. 75 (3), pp. 753.
Autor:
Phillips MM; Center for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute (BCI)-a Cancer Research UK Center of Excellence, Queen Mary University of London, John Vane Science Center, London, EC1M 6BQ, UK.; Department of Medical Oncology, Barts Health NHS Trust, St Bartholomew's Hospital, West Smithfield, London, EC1A 7BE, UK., Pavlyk I; Center for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute (BCI)-a Cancer Research UK Center of Excellence, Queen Mary University of London, John Vane Science Center, London, EC1M 6BQ, UK., Allen M; Center for Tumor Microenvironment, Barts Cancer Institute (BCI)-a Cancer Research UK Center of Excellence, Queen Mary University of London, John Vane Science Center, London, EC1M 6BQ, UK., Ghazaly E; Centre for Haemato-Oncology, Barts Cancer Institute (BCI)-a Cancer Research UK Center of Excellence, Queen Mary University of London, John Vane Science Center, London, EC1M 6BQ, UK.; Medicines and Healthcare Products Regulatory Agency (MHRA), London, UK., Cutts R; Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK., Carpentier J; Center for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute (BCI)-a Cancer Research UK Center of Excellence, Queen Mary University of London, John Vane Science Center, London, EC1M 6BQ, UK., Berry JS; Center for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute (BCI)-a Cancer Research UK Center of Excellence, Queen Mary University of London, John Vane Science Center, London, EC1M 6BQ, UK., Nattress C; Center for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute (BCI)-a Cancer Research UK Center of Excellence, Queen Mary University of London, John Vane Science Center, London, EC1M 6BQ, UK., Feng S; Center for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute (BCI)-a Cancer Research UK Center of Excellence, Queen Mary University of London, John Vane Science Center, London, EC1M 6BQ, UK., Hallden G; Center for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute (BCI)-a Cancer Research UK Center of Excellence, Queen Mary University of London, John Vane Science Center, London, EC1M 6BQ, UK., Chelala C; Center for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute (BCI)-a Cancer Research UK Center of Excellence, Queen Mary University of London, John Vane Science Center, London, EC1M 6BQ, UK., Bomalaski J; Polaris Pharmaceuticals, Inc., San Diego, CA, 92121, USA., Steele J; Department of Medical Oncology, Barts Health NHS Trust, St Bartholomew's Hospital, West Smithfield, London, EC1A 7BE, UK., Sheaff M; Department of Histopathology, Barts Health NHS Trust, Royal London Hospital, London, E1 1BB, UK., Balkwill F; Center for Tumor Microenvironment, Barts Cancer Institute (BCI)-a Cancer Research UK Center of Excellence, Queen Mary University of London, John Vane Science Center, London, EC1M 6BQ, UK., Szlosarek PW; Center for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute (BCI)-a Cancer Research UK Center of Excellence, Queen Mary University of London, John Vane Science Center, London, EC1M 6BQ, UK. p.w.szlosarek@qmul.ac.uk.; Department of Medical Oncology, Barts Health NHS Trust, St Bartholomew's Hospital, West Smithfield, London, EC1A 7BE, UK. p.w.szlosarek@qmul.ac.uk.
Publikováno v:
Pharmacological reports : PR [Pharmacol Rep] 2023 Jun; Vol. 75 (3), pp. 570-584. Date of Electronic Publication: 2023 Apr 03.
Autor:
Yao S; Departments of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Thoracic Surgery, Xuanwu Hospital, Capital Medical University, Beijing, China., Janku F; Departments of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Subbiah V; Departments of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Stewart J; Departments of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Patel SP; Departments of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kaseb A; Departments of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Westin SN; Departments of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Naing A; Departments of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Tsimberidou AM; Departments of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hong D; Departments of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Piha-Paul SA; Departments of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Shi N; Departments of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Johnston A; Polaris Pharmaceuticals, Inc., San Diego, CA, USA., Bomalaski J; Polaris Pharmaceuticals, Inc., San Diego, CA, USA., Fu S; Departments of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. siqingfu@mdanderson.org.
Publikováno v:
British journal of cancer [Br J Cancer] 2021 Apr; Vol. 124 (9), pp. 1533-1539. Date of Electronic Publication: 2021 Mar 05.
Autor:
Szyszko TA; King's College London and Guy's and St Thomas' PET Centre, St Thomas' Hospital, London, United Kingdom.; Department of Nuclear Medicine, Royal Free Hospital NHS Trust, London, United Kingdom.; Department of Oncology, University College London, London, United Kingdom., Dunn JT; King's College London and Guy's and St Thomas' PET Centre, St Thomas' Hospital, London, United Kingdom., Phillips MM; Department of Medical Oncology, St. Bartholomew's Hospital, Barts Health NHS Trust, London, United Kingdom., Bomalaski J; Polaris Pharmaceuticals Inc., San Diego, California., Sheaff MT; Department of Histopathology, Royal London Hospital, Barts Health NHS Trust, London, United Kingdom., Ellis S; Department of Diagnostic Imaging, St. Bartholomew's Hospital, Barts Health NHS Trust, London, United Kingdom., Pike L; King's College London and Guy's and St Thomas' PET Centre, St Thomas' Hospital, London, United Kingdom., Goh V; Cancer Imaging, School of Biomedical Engineering and Imaging Sciences, King's College London, London, United Kingdom., Cook GJR; King's College London and Guy's and St Thomas' PET Centre, St Thomas' Hospital, London, United Kingdom.; Cancer Imaging, School of Biomedical Engineering and Imaging Sciences, King's College London, London, United Kingdom., Szlosarek PW; Department of Medical Oncology, St. Bartholomew's Hospital, Barts Health NHS Trust, London, United Kingdom.; Centre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
Publikováno v:
JTO clinical and research reports [JTO Clin Res Rep] 2022 Jul 20; Vol. 3 (9), pp. 100382. Date of Electronic Publication: 2022 Jul 20 (Print Publication: 2022).
Autor:
Beddowes, E, Spicer, J, Chan, PY, Khadeir, R, Corbacho, JG, Repana, D, Steele, JP, Schmid, P, Szyszko, T, Cook, G, Diaz, M, Feng, X, Johnston, A, Thomson, J, Sheaff, M, Wu, B-W, Bomalaski, J, Pacey, S, Szlosarek, PW
Publikováno v:
Beddowes, E, Spicer, J, Chan, P Y, Khadeir, R, Garcia Corbacho, J, Repana, D, Steele, J P, Schmid, P, Szyszko, T, Cook, G, Diaz, M, Feng, X, Johnston, A, Thomason, J, Scheaff, M, Wu, B-W, Bomalaski, J, Pacey, S & Szlosarek, P W 2017, ' Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers ', Journal of Clinical Oncology, vol. 35, no. 16, pp. 1778-1785 . https://doi.org/10.1200/JCO.2016.71.3230
Purpose: Pegylated arginine deiminase (ADI-PEG 20) depletes essential amino acid levels in argininosuccinate synthetase 1 (ASS1) -negative tumors by converting arginine to citrulline and ammonia. The main aim of this study was to determine the recomm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16d3b5e67f628e85c2d09fcd2d9019a2
https://kclpure.kcl.ac.uk/ws/files/72158703/Phase_1_Dose_Escalation_Study_BEDDOWES_Publishedonline7April2017_GOLD_VoR_CC_BY_.pdf
https://kclpure.kcl.ac.uk/ws/files/72158703/Phase_1_Dose_Escalation_Study_BEDDOWES_Publishedonline7April2017_GOLD_VoR_CC_BY_.pdf
Autor:
Hajji N; John Fulcher Molecular Neuro-oncology Laboratory, Department Brain Sciences, Imperial College, London, United Kingdom., Garcia-Revilla J; Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, University of Seville, Seville, Spain.; Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío (HUVR)/CSIC, University of Seville, Seville, Spain., Soto MS; John Fulcher Molecular Neuro-oncology Laboratory, Department Brain Sciences, Imperial College, London, United Kingdom.; Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, University of Seville, Seville, Spain.; Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío (HUVR)/CSIC, University of Seville, Seville, Spain., Perryman R; John Fulcher Molecular Neuro-oncology Laboratory, Department Brain Sciences, Imperial College, London, United Kingdom., Symington J; John Fulcher Molecular Neuro-oncology Laboratory, Department Brain Sciences, Imperial College, London, United Kingdom., Quarles CC; Division of Neuroimaging Research, Barrow Neurological Institute, Phoenix, Arizona, USA., Healey DR; Division of Neuroimaging Research, Barrow Neurological Institute, Phoenix, Arizona, USA., Guo Y; Division of Neuroimaging Research, Barrow Neurological Institute, Phoenix, Arizona, USA., Orta-Vázquez ML; Department of Cell Biology, Faculty of Biology, University of Seville, Seville, Spain., Mateos-Cordero S; Department of Cell Biology, Faculty of Biology, University of Seville, Seville, Spain., Shah K; Center for Stem Cell Therapeutics and Imaging (CSTI), Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Bomalaski J; Polaris Pharmaceuticals Inc., San Diego, California, USA., Anichini G; John Fulcher Molecular Neuro-oncology Laboratory, Department Brain Sciences, Imperial College, London, United Kingdom., Tzakos AG; Department of Chemistry, University of Ioannina, Ioannina, Greece.; Institute of Materials Science and Computing, University Research Center of Ioannina, Ioannina, Greece., Crook T; John Fulcher Molecular Neuro-oncology Laboratory, Department Brain Sciences, Imperial College, London, United Kingdom., O'Neill K; John Fulcher Molecular Neuro-oncology Laboratory, Department Brain Sciences, Imperial College, London, United Kingdom., Scheck AC; Department of Child Health, University of Arizona College of Medicine, Phoenix, Arizona, USA., Venero JL; Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, University of Seville, Seville, Spain.; Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío (HUVR)/CSIC, University of Seville, Seville, Spain., Syed N; John Fulcher Molecular Neuro-oncology Laboratory, Department Brain Sciences, Imperial College, London, United Kingdom.
Publikováno v:
The Journal of clinical investigation [J Clin Invest] 2022 Mar 15; Vol. 132 (6).
Autor:
Przystal, JM, Hajji, N, Khozoie, C, Renziehausen, A, Zeng, Q, Abaitua, F, Hajitou, A, Suwan, K, Want, E, Bomalaski, J, Szlosarek, P, O'Neill, K, Crook, T, Syed, N
Publikováno v:
Cell Death & Disease
Cell Death and Disease, Vol 9, Iss 12, Pp 1-10 (2018)
Cell Death and Disease, Vol 9, Iss 12, Pp 1-10 (2018)
Glioblastoma multiforme (GBM) remains a cancer with a poor prognosis and few effective therapeutic options. Successful medical management of GBM is limited by the restricted access of drugs to the central nervous system (CNS) caused by the blood brai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::c296c17bc2d31f218b33cd1352dbdb3c
http://hdl.handle.net/10044/1/65835
http://hdl.handle.net/10044/1/65835
Autor:
Yao S; Department of Investigational Cancer Therapeutics, Houston, Texas, USA.; Department of Thoracic Surgery, Xuanwu Hospital, Capital Medical University, Beijing, China., Janku F; Department of Investigational Cancer Therapeutics, Houston, Texas, USA., Koenig K; Department of Breast Medical Oncology, Houston, Texas, USA., Tsimberidou AM; Department of Investigational Cancer Therapeutics, Houston, Texas, USA., Piha-Paul SA; Department of Investigational Cancer Therapeutics, Houston, Texas, USA., Shi N; Department of Investigational Cancer Therapeutics, Houston, Texas, USA., Stewart J; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Johnston A; Polaris Pharmaceuticals, Inc., San Diego, California, USA., Bomalaski J; Polaris Pharmaceuticals, Inc., San Diego, California, USA., Meric-Bernstam F; Department of Investigational Cancer Therapeutics, Houston, Texas, USA., Fu S; Department of Investigational Cancer Therapeutics, Houston, Texas, USA.
Publikováno v:
Cancer medicine [Cancer Med] 2022 Jan; Vol. 11 (2), pp. 340-347. Date of Electronic Publication: 2021 Nov 28.